Three-Pronged attack on aggressive breast cancer tested in new trial
NCT ID NCT07351487
Summary
This study is testing a three-drug combination given before surgery for triple-negative breast cancer (TNBC). The goal is to see if adding two newer drugs (sintilimab and bevacizumab) to standard chemotherapy can more effectively shrink or eliminate the tumor. Researchers will measure how many patients have no cancer left in the breast and lymph nodes after treatment and track side effects and long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.